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Antagonists of the substance P (SP) preferring neurokinin
1 receptor (NK1-R) represent a promising novel class of
drugs for the treatment of stress-related disorders includ-
ing depression and anxiety disorders. The underlying neu-
ronal mechanisms involved in the effects of these drugs,
however, are poorly understood. By using in vivo micro-
dialysis we observed increased SP, but reduced serotonin
(5-HT) release during forced swim stress (FST) in the rat
lateral septum (LS), a key area in processing emotions and
stress responses. Acute administration of the selective
high affinity NK1-R antagonist L-822429 injected either
systemically or locally into the LS reversed the FST-
induced decrease in 5-HT efflux and facilitated active cop-
ing strategies during the FST. Increased active coping in
the FST was attenuated by intraseptal 5-HT1A-R blockade
with WAY100635, indicating that the behavioural effect
during NK1-R blockade is mediated by enhanced intrasep-
tal serotonergic transmission acting on 5-HT1A-R. Taken
together, our findings identify the LS as an important
brain area for the modulation of stress responses by the
SP/NK1-R system. NK1-R blockade resulted in behavio-
rally significant enhancement of 5-HT transmission. We
show for the first time that this modulation does not nec-
essarily involve interaction with neuronal firing at the cell
body level of 5-HT neurons as previously postulated, but
can be elicited in a terminal region of these neurons.
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